KESTRA MEDICAL TECHNOLOGIES, LTD.
For the period ended Jan 31, 2025. Filed Apr 17, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jan 31, 2025 · Filed Apr 17, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
| Three Months Ended January 31, | Nine Months Ended January 31, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Revenue | $15,090 | $8,277 | $42,582 | $17,760 |
| Costs of revenue | 8,543 | 7,397 | 26,005 | 18,795 |
| Gross margin | 6,547 | 880 | 16,577 | (1,035) |
| Operating expenses: | ||||
| Research and development costs | 3,353 | 3,735 | 10,266 | 11,669 |
| Selling, general and administrative | 23,795 | 17,091 | 64,477 | 52,010 |
| Total operating expenses | 27,148 | 20,826 | 74,743 | 63,679 |
| Loss from operations | (20,601) | (19,946) | (58,166) | (64,714) |
| Other expense (income): | ||||
| Interest expense | 1,783 | 1,651 | 5,974 | 4,295 |
| Interest income | (628) | — | (1,543) | — |
| Other expense (income) | (15) | 8 | 73 | 2,776 |
| Net loss before provision for income taxes | (21,741) | (21,605) | (62,670) | (71,785) |
| Provision for income taxes | 18 | 14 | 33 | 51 |
| Net loss and comprehensive loss | (21,759) | (21,619) | (62,703) | (71,836) |
| Net loss attributable to non-controlling interest | (250) | — | (942) | — |
| Net loss and comprehensive loss attributable to West Affum Intermediate Holdings Corp. | (21,509) | (21,619) | (61,761) | (71,836) |
| Less: Undeclared preferred stock dividends | 3,324 | 1,812 | 9,030 | 4,727 |
| Net loss attributable to common stockholder, basic and diluted | $(24,833) | $(23,431) | $(70,791) | $(76,563) |
| Net loss per share attributable to common stockholder, basic and diluted | $(1.25) | $(1.18) | $(3.56) | $(3.85) |
| Weighted-average shares of common stock outstanding, basic and diluted1 | 19,885,382 | 19,885,382 | 19,885,382 | 19,885,382 |
1 Weighted-average shares of common stock outstanding, basic and diluted, has been adjusted on a retrospective basis. Refer to Note 16 “Net Loss Per Share Attributable to Common Stockholder” for additional disclosure.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE PREFERRED STOCK AND
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.